Holen Sie sich die Stockscreener-App
2.335
3.11%
-0.075
Schlusskurs vom Vortag:
$2.41
Offen:
$2.42
24-Stunden-Volumen:
85,719
Relative Volume:
0.11
Marktkapitalisierung:
$325.82M
Einnahmen:
$79,600
Nettoeinkommen (Verlust:
$-48.26M
KGV:
-4.744
EPS:
-0.4922
Netto-Cashflow:
$-28.24M
1W Leistung:
-6.60%
1M Leistung:
+7.11%
6M Leistung:
+13.90%
1J Leistung:
+29.72%
1-Tages-Spanne:
$2.335
$2.44
1-Wochen-Bereich:
$2.335
$2.54
52-Wochen-Spanne:
$1.33
$2.54
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Firmenname
Inhibikase Therapeutics Inc
Sektor
Branche
Telefon
(302) 295-3800
Adresse
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Compare IKT vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
2.335 | 327.91M | 79,600 | -48.26M | -28.24M | -0.4922 |
VRTX
Vertex Pharmaceuticals Inc
|
542.23 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
797.65 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,022.57 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
139.17 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
204.38 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-04 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2026-01-21 | Eingeleitet | BofA Securities | Buy |
| 2025-12-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-12-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Herabstufung | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc Aktie (IKT) Neueste Nachrichten
Inhibikase (IKT) Q1 2026 Results: EPS Prints Above Forecast; Post-Earnings: Shares Finish 0.42% Higher at the CloseFree Cash Flow Trends - vinanet.vn
Inhibikase Loss Widens as Phase 3 PAH Trial Expands - MyChesCo
Inhibikase Therapeutics (IKT) Slips 1.5% as Shares Test Support at $2.25Shakeout Pattern - vinanet.vn
Inhibikase Therapeutics (IKT) Holds Steady at $2.41 as Shares Consolidate Between $2.29 Support and $2.53 ResistanceReversal Setup Alerts - vinanet.vn
Perceptive group (IKT) discloses 6.9% Inhibikase stake through 10.3M warrant shares - Stock Titan
Nantahala reports 4.30% Inhibikase (IKT) stake across 5.81M shares - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Sands Capital group (NASDAQ: IKT) discloses 9.3% Inhibikase stake plus large warrants - Stock Titan
Oppenheimer Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Inhibikase Therapeutics Faces Rising BIOSECURE, China Supply Chain and Trial Risks That Could Disrupt Growth - TipRanks
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Is Inhibikase Therapeutics Inc (IKT) Positioned for Growth After Reporting $0.11 Loss? GF Score: 36/100 - GuruFocus
LifeSci Capital Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Inhibikase Q2 EPS of $(0.11) meets analyst consensus estimates - scanx.trade
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity - Yahoo Finance
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a shareEarnings Preview - TradingView
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Perceptive Advisors LLC Sells 3,106,568 Shares of Inhibikase Therapeutics, Inc. $IKT - MarketBeat
Inhibikase Therapeutics (IKT) Declines 4.4% as Stock Pressures Key $2.07 Support ZoneBreadth Thrust - dars.gov.et
Inhibikase Therapeutics, Inc. Revenue Breakdown – NASDAQ:IKT - TradingView
Inhibikase Wins FDA Orphan Status for PAH Drug Candidate - MyChesCo
18,030,000-share swap for warrant by Inhibikase Therapeutics, Inc. (IKT) - Stock Titan
H.C. Wainwright reiterates Inhibikase stock rating on FDA orphan drug status - Investing.com Canada
RA Capital group (NASDAQ: IKT) discloses 9.99% capped stake via stock and warrants - Stock Titan
Inhibikase Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Progress Continues - dars.gov.et
Inhibikase Therapeutics (IKT) Slips 1% as Shares Test Key Support at $2.21AI Trade Signals - vinanet.vn
Inhibikase Therapeutics Inc (IKT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Inhibikase Therapeutics Inc (IKT) Cash Flow - TradingKey
Inhibikase Therapeutics Inc (IKT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Inhibikase Therapeutics, Inc. $IKT Position Boosted by Kalehua Capital Management LLC - MarketBeat
Inhibikase Therapeutics, Inc. Revenue Breakdown – BOATS:IKT - TradingView
IKT|Inhibikase Therapeutics Inc|Price:2.330| - TradingKey
TradingKey - TradingKey
IKT|Inhibikase Therapeutics Inc|Price:2.355|Chg%:+0.025 - TradingKey
Inhibikase Therapeutics Inc (IKT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Inhibikase Therapeutics (NASDAQ:IKT) Rating Increased to Sell at Wall Street Zen - MarketBeat
Inhibikase Therapeutics Inc (IKT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
RA CAPITAL MANAGEMENT, L.P. Acquires 25 Million Shares in Inhibi - GuruFocus
Inhibikase Therapeutics (IKT) Secures Orphan Drug Designation fr - GuruFocus
$Inhibikase Therapeutics (IKT.US)$ - Moomoo
Inhibikase Gains FDA Orphan Drug Status for IKT-001 - TipRanks
Inhibikase Therapeutics (IKT) Secures Orphan Drug Designation from FDA - GuruFocus
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH - The Manila Times
Inhibikase's IKT-001 gets FDA orphan designation for PAH, about 50,000 Americans - Stock Titan
Inhibikase Therapeutics (IKT) Surges 7.4%: Testing Key Resistance at $2.45VWAP Bounce - vinanet.vn
Inhibikase Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition - Moomoo
Frontier tech research, news & data - MLQ.ai
RA Capital Management files initial beneficial ownership statement in Inhibikase Therapeutics - Bitget
Inhibikase Q1 2026 Earnings: Better-Than-Expected Loss Buoys Shares After Market CloseShort-Term Outlook - vinanet.vn
Inhibikase Therapeutics (NASDAQ:IKT) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Finanzdaten der Inhibikase Therapeutics Inc-Aktie (IKT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Inhibikase Therapeutics Inc-Aktie (IKT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sands Capital Life Sciences Pu | 10% Owner |
Nov 21 '25 |
Buy |
1.45 |
2,068,965 |
2,999,999 |
13,018,965 |
0.85%
1.52%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):